Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Public ClinicalTrials.gov record NCT05771428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating symptoms of early AD. Adverse events, change in disease activity, how ABBV-552 moves through body of participants and the body response to ABBV-552 will be assessed. ABBV-552 is an investigational drug being developed for the treatment of Alzheimer's disease (AD). Study doctors put the participants in 1 of 4 groups (3 active dose groups and a placebo group), called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Approximately 240 participants aged 50-90 years with mild AD will be enrolled in approximately 60 sites across the world. Participants will receive oral ABBV-552 or placebo capsules once daily for 12 weeks and followed for 30 days after the last dose of study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT05771428
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 263 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2023 (Actual)
- Primary completion
- Aug 6, 2024 (Actual)
- Completion
- Sep 12, 2024 (Actual)
- Last update posted
- Oct 15, 2025
2023 – 2024
United States locations
- U.S. sites
- 37
- U.S. states
- 15
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Irvine Clinical Research /ID# 250030 | Irvine | California | 92614 | — |
| Alliance for Research Alliance for Wellness /ID# 246492 | Long Beach | California | 90807 | — |
| Wake Research - Pharmacology Research Institute (WR-PRI), LLC (Alamitos) /ID# 248891 | Los Alamitos | California | 90720 | — |
| New England Institute for Clinical Research /ID# 246488 | Stamford | Connecticut | 06905 | — |
| Vertex Research Group Inc /ID# 248295 | Clermont | Florida | 34711-5037 | — |
| Finlay Medical Research - West Palm Beach /ID# 246970 | Greenacres City | Florida | 33467-2979 | — |
| Velocity Clinical Research - Hallandale Beach /ID# 246896 | Hallandale | Florida | 33009-4427 | — |
| New Life Medical Research Center - Hialeah /ID# 247536 | Hialeah | Florida | 33012 | — |
| K2 Medical Research - The Villages /ID# 250820 | Lady Lake | Florida | 32159-8975 | — |
| Allied Biomedical Res Inst Inc /ID# 246971 | Miami | Florida | 33155 | — |
| Ivetmar Medical Group, LLC. /ID# 247670 | Miami | Florida | 33155 | — |
| New Horizon Research Center /ID# 248298 | Miami | Florida | 33165-3372 | — |
| K2 Medical Research - Ocoee /ID# 251029 | Ocoee | Florida | 34761-4547 | — |
| Health Synergy Clinical Research LLC /ID# 247726 | Okeechobee | Florida | 34972-2568 | — |
| K2 Medical Research - Orlando - South Orlando Avenue /ID# 250904 | Orlando | Florida | 32751 | — |
| Combined Research Orlando Phase I-IV /ID# 247697 | Orlando | Florida | 32814 | — |
| Alzheimer's Research and Treatment Center - Stuart /ID# 246484 | Stuart | Florida | 34997-5765 | — |
| Alzheimer's Research and Treatment Center - Wellington /ID# 246491 | Wellington | Florida | 33414 | — |
| Conquest Research /ID# 262078 | Winter Park | Florida | 32789 | — |
| Columbus Memory Center /ID# 249534 | Columbus | Georgia | 31909 | — |
| Northwest Clinical Trials /ID# 248663 | Boise | Idaho | 83704 | — |
| Indiana University Health, Inc. /ID# 248300 | Fort Wayne | Indiana | 46804 | — |
| Josephson-Wallack-Munshower Neurology - Northeast /ID# 248554 | Indianapolis | Indiana | 46256 | — |
| University of Kentucky Sanders-Brown Center on Aging /ID# 251139 | Lexington | Kentucky | 40504 | — |
| NeuroMedical Clinic of Central Louisiana /ID# 246960 | Alexandria | Louisiana | 71301-3900 | — |
| Tandem Clinical Research, LLC /ID# 246973 | Marrero | Louisiana | 70072-3156 | — |
| Adams Clinical /ID# 248358 | Watertown | Massachusetts | 02472 | — |
| Velocity Clinical Research, Inc /ID# 249837 | Raleigh | North Carolina | 27607 | — |
| American Clinical Research Institute (ACRI) - Beavercreek /ID# 246930 | Beavercreek | Ohio | 45432-2886 | — |
| NeuroScience Research Center - Canton /ID# 248552 | Canton | Ohio | 44718-2784 | — |
| Neurology Diagnostics - South /ID# 246931 | Dayton | Ohio | 45459-4296 | — |
| Duplicate_Summit Headlands LLC /ID# 250678 | Portland | Oregon | 97210 | — |
| Vanderbilt Ingram Cancer Center /ID# 248801 | Nashville | Tennessee | 37232-0021 | — |
| Kerwin Medical Center /ID# 248662 | Dallas | Texas | 75231-4316 | — |
| ANESC Research LLC /ID# 246958 | El Paso | Texas | 79912 | — |
| Epic Medical Research /ID# 249141 | Red Oak | Texas | 75154-3981 | — |
| Sentara Neurology Specialists - Norfolk /ID# 248578 | Norfolk | Virginia | 23510-1065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05771428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05771428 live on ClinicalTrials.gov.